20 13,10/On the evening of October 24th, Hansen Pharmaceutical announced that it planned to acquire 80% equity of Yunnan Yongzitang Pharmaceutical Co., Ltd. in cash of 280 million yuan. Liu Lin 'an, chairman of Hansen Pharmaceutical, said: The main purpose of acquiring Yongzitang Pharmaceutical is to combine the exclusive variety advantage of Yongzitang with the strong sales ability of Hansen Pharmaceutical to realize industrial synergy and complementary advantages. In addition, the acquisition of Hansen Pharmaceutical will adopt all cash acquisition methods, which shows that the company's cash flow is stable and abundant.
Liu Lin 'an said that since Hansen Pharmaceutical went public, the company hopes to achieve leap-forward development through industry mergers and acquisitions. To this end, Hansen Pharmaceutical has visited more than 60 companies in the past three years. Hansen Pharmaceutical's primary standard for M&A goal is to have exclusive drug varieties.